Hormonal
Tight glycemic control (HbA1c ≤ 6.5%) in Type 2 Diabetes does not significantly reduce major cardiovascular events or all-cause mortality compared to standard control, and may increase mortality and hypoglycemia risk.
For Type 2 Diabetics, aiming for an A1c of 7% or slightly higher (if safe) is often as effective for heart protection as aiming for very low numbers (≤6.5%), while avoiding the risks of severe hypoglycemia and weight gain. Focus on overall cardiovascular risk management (blood pressure, lipids) rather than obsessing over ultra-tight glucose control, unless you are newly diagnosed with Type 1 Diabetes.
Current research fail to show that intensive glycemic control (HbA1c ≤ 6.5%) has a significant CV advantage as compared to conventional glycemic control targets (HbA1c of 7%-7.9%) in patients with T2DM... Furthermore, very tight glycemic control (HbA1c ≤ 6%), as seen in the ACCORD trial, may also place patients at more hazard of hypoglycemia, weight benefit and all reason mortality.
Why this rating
Based on multiple large-scale randomized controlled trials (UKPDS, VADT, ADVANCE, ACCORD, DCCT/EDIC).
Source
review on epidemiology, biochemical characteristics, treatment suggestions, and continued studies on diabetes and cardiovascular disease
Rajni Yadav · International Journal of Health Sciences · 2022
DOI 10.53730/ijhs.v6ns3.7084
More from this paper
- Intensive blood pressure control (Systolic < 120 mmHg) in Type 2 Diabetes does not reduce major cardiovascular events compared to standard control (< 140 mmHg) and increases adverse events like hypotension and renal failure.Strong
- Modest weight loss (5%) in Type 2 Diabetes improves cardiovascular risk factors (lipids, glucose) but evidence for reducing actual cardiovascular mortality or events is mixed and inconclusive.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →